Former FDA official Sklamberg On Objectivity In 483s, Assessing Quality Culture
Executive Summary
Former US FDA Deputy Commissioner for Global Regulatory Operations and Policy, Howard Sklamberg, shares his views at a conference in India on a range of issues, including the need for formal policy mechanisms to help infuse improved objectivity around Form 483 observations and challenges on evaluating quality culture.
You may also be interested in...
Data Integrity And The Iceberg Concern
US FDA official outlines a number of issues around data integrity lapses, including how they trigger concern around all records of a non-compliant firm and that certain factors, including the limited oversight of sponsors over CMOs, could potentially be linked with data integrity problems.
Former FDA Official Calls For 483 Reforms, Notes Caveats
Public scrutiny has made 483 results much more impactful than intended, says Howard Sklamberg, former FDA deputy commissioner for global regulatory operations and policy. He reminds stakeholders that information in them is preliminary.
India IPR Realities: Pharma, Legal Heads Discuss Winds Of Change, ‘Damocles Sword’
Leaders from Novartis, Bayer, Sun Pharma, the Indian Pharmaceutical Alliance, Médecins Sans Frontières and Anand and Anand discuss India’s evolving intellectual property rights landscape, including pre-grant oppositions, enforcement action and other realities. Concerns around evergreening, restrictions on patent-eligible subject matter and compulsory licensing were also key talking points at a recent conference in Hyderabad.